ReviewDrug design, development and therapy2017
Resveratrol as a potential therapeutic drug for respiratory system diseases.
Review in Drug design, development and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Protective effects of resveratrol in animal models of chronic obstructive pulmonary disease: a preclinical systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19).Scientific reports · 2022Trial
- Association between polyphenols and inhalation-induced oxidative stress in chronic lung diseases: A systematic review.Biomedical reports · 2026Article
- AhR as a Common Denominator in Immunity and Inflammation in Chronic Lung Diseases: Molecular and Clinical Insights.Diseases (Basel, Switzerland) · 2026Review
- Evaluation of Phytochemical Constituents, Antioxidant Potential, and Toxicological Profile of Selected Medicinal Plants from Romania's Spontaneous Flora.Molecules (Basel, Switzerland) · 2026Article
- Beyond the pill: incrimination of nuclear factor-kappa B and their targeted phytomedicine for pulmonary fibrosis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Pterostilbene and resveratrol: Exploring their protective mechanisms against skin photoaging - A scoping review.Biochemistry and biophysics reports · 2025Review
- Natural Products for the Management of Asthma and COPD.Handbook of experimental pharmacology · 2025Review
- Pre-asthma: a useful concept? A EUFOREA paper. Part 2-late onset eosinophilic asthma.Frontiers in allergy · 2024Review
- The Utilization of Plant-Material-Loaded Vesicular Drug Delivery Systems in the Management of Pulmonary Diseases.Current issues in molecular biology · 2023Review
- Resveratrol in the treatment of asthma based on an animal model.Postepy dermatologii i alergologii · 2022Review
- PGC-1α activity and mitochondrial dysfunction in preterm infants.Frontiers in physiology · 2022Review
- Randomized Double-blind Placebo-controlled Proof-of-concept Trial of Resveratrol for Outpatient Treatment of Mild Coronavirus Disease (COVID-19).Research square · 2021Article
- Article
- Resveratrol alleviates alveolar epithelial cell injury induced by hyperoxia by reducing apoptosis and mitochondrial dysfunction.Experimental biology and medicine (Maywood, N.J.) · 2021Article
- Ocular Delivery of Polyphenols: Meeting the Unmet Needs.Molecules (Basel, Switzerland) · 2021Review
- Network Pharmacology Reveals That Resveratrol Can Alleviate COVID-19-Related Hyperinflammation.Disease markers · 2021Article
- Clinical Evidence of Tai Chi Exercise Prescriptions: A Systematic Review.Evidence-based complementary and alternative medicine : eCAM · 2021Review
- Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis.Frontiers in pharmacology · 2021Review
- Prophylactic effect of resveratrol and piperine on pristane-induced murine model of lupus-like disease.Inflammopharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory system diseases are common and major ailments that seriously endanger human health. Resveratrol, a polyphenolic phytoalexin, is considered an anti-inflammatory, antioxidant, and anticancer agent. Thanks to its wide range of biological activities, resveratrol has become a hotspot in many fields, including respiratory system diseases. Indeed, research has demonstrated that resveratrol is helpful to relieve pulmonary function in the general population. Meanwhile, growing evidence indicates that resveratrol plays a protective role in respiratory system diseases. This review aimed to summarize the main protective effects of resveratrol in respiratory system diseases, including its anti-inflammatory, antiapoptotic, antioxidant, antifibrotic, antihypertensive, and anticancer activities. We found that resveratrol plays a protective role in the respiratory system through a variety of mechanisms, and so it may become a new drug for the treatment of respiratory system diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.